10:28 AM EDT, 07/15/2024 (MT Newswires) -- (Updates with Novo Nordisk's ( NVO ) statement in the headline and first four paragraphs.)

Novo Nordisk ( NVO ) said Monday that there is no meeting scheduled for this week between its senior executives and US Senate aides.

"In terms of meetings, we have agreed to participate in the Senate HELP Committee hearing in early September - there are no other meetings with our senior executives scheduled for us at this time," the company said in an emailed statement to MT Newswires.

Reuters reported Saturday, citing two sources familiar with the matter, that Novo executives were scheduled to meet with Democratic US Senate aides on Tuesday to discuss the repercussions of the company's decision to stop selling Levemir in the United States.

The company said it is discontinuing the Levemir insulin brand in the US due to global manufacturing constraints, a decline in patient access, and the availability of alternative insulin options in the market.

"Levemir has been off patent for a number of years and another manufacturer could produce the drug should they choose to," Novo Nordisk ( NVO ) said.

Price: 142.36, Change: +0.28, Percent Change: +0.20